

Supplementary Table S2. Gender differences in patients that switched and combined Device Aided Therapy (DAT). The median values and range (in brackets) are presented. PD=Parkinson's disease, GI= Global Improvement.

	Age at PD onset	PD duration at 1 <sup>st</sup> DAT	Age at 1 <sup>st</sup> DAT	Duration of 1 <sup>st</sup> DAT	Age at 2 <sup>nd</sup> DAT	Duration 2 <sup>nd</sup> DAT	GI after 1 <sup>st</sup> DAT	GI after 2 <sup>nd</sup> DAT
Females (n=12)	48.5 (29-69)	11.5 (3-20)	63 (38-72)	1.75 (0.08-11)	66.5 (44-76)	3 (0.08-8)	1.5 (1-5)	2 (1-4)
Males (n=18)	50.5 (36-66)	10 (6-28)	60 (44-75)	3 (0.5-18)	67 (39-79)	2.5 (0.08-9)	2 (1-6)	2 (1-4)
Mann-Whitney <i>U</i>	21.5	18.5	23	17.5	18.5	19	23.5	15.5
<i>p</i> -value	0.746	0.474	0.897	0.398	0.473	0.511	0.945	0.249

Supplementary Table S3. Differences between between different groups of patients that switched from one to another Device Aided Therapy (DAT). The median values and range (in brackets) are presented. **Significant values are written in bold.** PD=Parkinson's disease, GI= Global Improvement, CSAI=Continuous subcutaneous apomorphine infusion, LCIG=Levodopa-carbidopa intestinal gel infusion, and STN-DBS=Deep brain stimulation of the subthalamic nucleus.

	Age at PD onset	PD duration at 1 <sup>st</sup> DAT	Age at 1 <sup>st</sup> DAT	Duration of 1 <sup>st</sup> DAT	Age at 2 <sup>nd</sup> DAT	Duration of 2 <sup>nd</sup> DAT	GI after 1 <sup>st</sup> DAT	GI after 2 <sup>nd</sup> DAT	Widloxon Z <i>p</i> -value
LCIG-to-STN-DBS (n=7)	45 (29-50)	11 (9-28)	59 (38-69)	4 (1-11)	66 (44-73)	3 (2-8)	3 (1-3)	2 (1-3)	-0.55, <i>p</i> =0.581
CSAI-to-STN-DBS (n=5)	43 (36-52)	8 (8-13)	52 (44-65)	1 (1-2)	54 (39-67)	2 (1-9)	2 (1-2)	1 (1-3)	-1.00, <i>p</i> =0.317
CSAI-to-LCIG (n=8)	55 (48-66)	12 (7-20)	70 (58-74)	1.5 (0.5-5)	72 (59-77)	2.75 (0.5-5)	2 (1-3)	2 (1-3)	0.00, <i>p</i> =1.000
Kruskal Wallis <i>H</i>	<b>9.03</b>	3.14	<b>8.25</b>	3.26	<b>7.66</b>	0.83	0.70	2.35	/
<i>p</i> -value	<b>0.011</b>	0.110	<b>0.016</b>	0.196	<b>0.022</b>	0.662	0.705	0.309	/

Supplementary Table S4. Differences between patients who switched Device Aided Therapy (DAT) and patients who combined DAT. The median values and range (in brackets) are presented. **Significant values are written in bold.** PD=Parkinson's disease, GI= Global Improvement.

	Age at PD onset	PD duration at 1 <sup>st</sup> DAT	Age at 1 <sup>st</sup> DAT	Duration of 1 <sup>st</sup> DAT	Age at 2 <sup>nd</sup> DAT	Duration of 2 <sup>nd</sup> DAT	GI after 1 <sup>st</sup> DAT	GI after 2 <sup>nd</sup> DAT	Wilcoxon Z <i>p</i> -value
Switched (n=24)	<b>49 (29-66)</b>	<b>10 (7-28)</b>	60 (38-74)	<b>1.75 (0.08-18)</b>	66 (39-77)	3 (0.08-9)	<b>2(1-6)</b>	2(1-4)	-0.91, p=0.327
Combined (n=6)	<b>55 (46-69)</b>	<b>7 (3-11)</b>	62 (57-75)	<b>5 (3-10)</b>	68 (64-79)	3 (0.08-5)	<b>1 (1-1)</b>	1.5 (1-2)	-1.72, p=0.083
Mann-Whitney <i>U</i>	<b>30.5</b>	<b>29.0</b>	57.5	<b>27.5</b>	41.5	67.5	<b>18.0</b>	49.5	/
<i>p</i> -value	<b>0.031</b>	<b>0.025</b>	0.452	<b>0.020</b>	0.113	0.813	<b>0.003</b>	0.251	/